EUVIMEDEUVIMED entdecken
Crossref

Secosteroid–quinoline hybrids as new anticancer agents

Alexey I Ilovaisky, Alexander M Scherbakov, Valentina M Merkulova, Elena I Chernoburova, Marina A Shchetinina, Olga E Andreeva, Diana I Salnikova, Igor V Zavarzin, Alexander O Terent'ev

The Journal of Steroid Biochemistry and Molecular Biology · 2023-04 · 228 · 106245

DOI: 10.1016/j.jsbmb.2022.106245 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Journal of Steroid Biochemistry and Molecular Biology, 2023-04. Verfasst von Alexey I Ilovaisky und 8 weiteren Autor:innen. Beteiligte Einrichtung: N. D. Zelinsky Institute of Organic Chemistry, Russian Academy of Sciences, Leninsky prospect 47, Moscow 119991, Russia. Electronic address: ilov@ioc…. Hauptthemen laut MEDLINE: Antineoplastic Agents, Quinolines, Secosteroids. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 65 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

An elegant approach to unknown secosteroid-quinoline hybrids is disclosed. A series of 13,17-secoestra-1,3,5(10)-trien-17-oic acid [N'-(iso)quinolylmethylene]hydrazides was prepared and these novel type of secosteroids was screened for antiproliferative activity against estrogen-responsive human breast cancer cell line MCF-7. Most of the synthesized compounds showed a cytotoxic effect superior to that of reference drug cisplatin; the lead compound exhibits the highest activity with the IC50 value of about 0.8 μM and is 7 times more active than cisplatin. A high selectivity index was observed for the hit 13,17-secoestra-1,3,5(10)-trien-17-oic acid [N'-quinolylmethylene]hydrazides 2a and 2c. Compounds 2a and 2c evaluated in luciferase reporter assays exhibited high antiestrogenic potency which was superior to that of tamoxifen. These hit compounds were characterized by high activity against MCF-7 cells that retained towards multidrug-resistant NCI/ADR-RES cells.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic AgentsQuinolinesSecosteroidsHumansCell Line, TumorCisplatinTrientineStructure-Activity RelationshipDrug Screening Assays, AntitumorCell ProliferationMolecular Structure

Stichwörter der Autor:innen

AzomethinesBreast cancerCytotoxicityEstrogen receptor αHydrazidesQuinolinesSecosteroids

Substanzen

CisplatinTrientineAntineoplastic AgentsQuinolinesSecosteroids

Autor:innen und Institutionen

  • N. D. Zelinsky Institute of Organic Chemistry, Russian Academy of Sciences, Leninsky prospect 47, Moscow 119991, Russia. Electronic address: ilov@ioc.ac.ru.
  • N.N. Blokhin National Medical Research Center of Oncology, Kashirskoye shosse 24, Moscow 115478, Russia.
  • N. D. Zelinsky Institute of Organic Chemistry, Russian Academy of Sciences, Leninsky prospect 47, Moscow 119991, Russia.
  • N. D. Zelinsky Institute of Organic Chemistry, Russian Academy of Sciences, Leninsky prospect 47, Moscow 119991, Russia. Electronic address: alterex@yandex.ru.

Zitieren

APA

Ilovaisky, A. I., Scherbakov, A. M., Merkulova, V. M., Chernoburova, E. I., Shchetinina, M. A., Andreeva, O. E., Salnikova, D. I., Zavarzin, I. V., & Terent'ev, A. O. (2023). Secosteroid–quinoline hybrids as new anticancer agents. The Journal of Steroid Biochemistry and Molecular Biology, 228, 106245. https://doi.org/10.1016/j.jsbmb.2022.106245

Vancouver

Ilovaisky AI, Scherbakov AM, Merkulova VM, Chernoburova EI, Shchetinina MA, Andreeva OE, et al. Secosteroid–quinoline hybrids as new anticancer agents. The Journal of Steroid Biochemistry and Molecular Biology. 2023;228:106245. doi:10.1016/j.jsbmb.2022.106245

BibTeX
@article{Ilovaisky2023,
  author = {Ilovaisky, Alexey I and Scherbakov, Alexander M and Merkulova, Valentina M and Chernoburova, Elena I and Shchetinina, Marina A and Andreeva, Olga E and Salnikova, Diana I and Zavarzin, Igor V and Terent'ev, Alexander O},
  title = {Secosteroid–quinoline hybrids as new anticancer agents},
  journal = {The Journal of Steroid Biochemistry and Molecular Biology},
  year = {2023},
  volume = {228},
  pages = {106245},
  doi = {10.1016/j.jsbmb.2022.106245}
}
Kostenlos starten →